Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
Chronic fecal incontinence (FI) often causes profound emotional distress leading to social withdrawal and isolation.3 Clinical studies demonstrate that sacral neuromodulation (SNM) delivered by the InterStim™ systems is safe, effective, and may offer your patients improved quality of life.1,2
SNM therapy delivered by the InterStim™ systems may help patients that failed or could not tolerate more conservative treatments reduce their FI symptoms.1,2
See evidence of how the efficacy of the InterStim™ systems compare to optimal medical therapy (OMT).
View five year data of InterStim™ systems for bowel control.
Clinical data using the InterStim™ systems for bowel control show no unanticipated adverse device effects, no patient deaths related to the neurostimulator or therapy, and no surgical injuries during the test or implant procedures.1,2
The most common adverse events experienced during clinical studies included pain at implant sites, new pain, lead migration, infection, technical or device problems, adverse change in bowel or voiding function, and undesirable stimulation or sensations. Any of these may require additional surgery or cause return of symptoms.2
For additional safety information, please refer to Indications, Safety, and Warnings.
Review a summary of product performance data from the Medtronic post-market registry.EXPLORE THE DATA
Review product advisories for sacral neuromodulation that help us provide the highest quality products and services.VIEW THE ARCHIVE
Wexner SD, Coller JA, Devroede G, et al. Sacral nerve stimulation for fecal incontinence: results of a 120-patient prospective multicenter study. Ann Surg. 2010;251(3):441-449.
Medtronic InterStimTM Clinical Summary, 2018.
Brown HW, Wexner SD, Segall MM, Brezoczky KL, Lukacz ES. Quality of life impact in women with accidental bowel leakage. Int J Clin Pract. 2012;66(11):1109-1116.